152 related articles for article (PubMed ID: 12435730)
1. A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571.
Böhmer FD; Karagyozov L; Uecker A; Serve H; Botzki A; Mahboobi S; Dove S
J Biol Chem; 2003 Feb; 278(7):5148-55. PubMed ID: 12435730
[TBL] [Abstract][Full Text] [Related]
2. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.
Sattler M; Scheijen B; Weisberg E; Griffin JD
Adv Exp Med Biol; 2003; 532():121-40. PubMed ID: 12908554
[TBL] [Abstract][Full Text] [Related]
3. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia.
Sawyers CL
Cancer Cell; 2002 Jun; 1(5):413-5. PubMed ID: 12124170
[TBL] [Abstract][Full Text] [Related]
4. Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors.
Canning P; Tan L; Chu K; Lee SW; Gray NS; Bullock AN
J Mol Biol; 2014 Jun; 426(13):2457-70. PubMed ID: 24768818
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.
Heinrich MC; Griffith DJ; Druker BJ; Wait CL; Ott KA; Zigler AJ
Blood; 2000 Aug; 96(3):925-32. PubMed ID: 10910906
[TBL] [Abstract][Full Text] [Related]
6. Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3.
Teller S; Krämer D; Böhmer SA; Tse KF; Small D; Mahboobi S; Wallrapp C; Beckers T; Kratz-Albers K; Schwäble J; Serve H; Böhmer FD
Leukemia; 2002 Aug; 16(8):1528-34. PubMed ID: 12145694
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase.
Mol CD; Dougan DR; Schneider TR; Skene RJ; Kraus ML; Scheibe DN; Snell GP; Zou H; Sang BC; Wilson KP
J Biol Chem; 2004 Jul; 279(30):31655-63. PubMed ID: 15123710
[TBL] [Abstract][Full Text] [Related]
8. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).
Nagar B; Bornmann WG; Pellicena P; Schindler T; Veach DR; Miller WT; Clarkson B; Kuriyan J
Cancer Res; 2002 Aug; 62(15):4236-43. PubMed ID: 12154025
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
[TBL] [Abstract][Full Text] [Related]
10. Flt3 receptor tyrosine kinase as a drug target in leukemia.
Schmidt-Arras D; Schwäble J; Böhmer FD; Serve H
Curr Pharm Des; 2004; 10(16):1867-83. PubMed ID: 15180525
[TBL] [Abstract][Full Text] [Related]
11. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
O'Farrell AM; Abrams TJ; Yuen HA; Ngai TJ; Louie SG; Yee KW; Wong LM; Hong W; Lee LB; Town A; Smolich BD; Manning WC; Murray LJ; Heinrich MC; Cherrington JM
Blood; 2003 May; 101(9):3597-605. PubMed ID: 12531805
[TBL] [Abstract][Full Text] [Related]
12. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis.
Griswold IJ; Shen LJ; La Rosée P; Demehri S; Heinrich MC; Braziel RM; McGreevey L; Haley AD; Giese N; Druker BJ; Deininger MW
Blood; 2004 Nov; 104(9):2912-8. PubMed ID: 15242881
[TBL] [Abstract][Full Text] [Related]
13. STI-571: an anticancer protein-tyrosine kinase inhibitor.
Roskoski R
Biochem Biophys Res Commun; 2003 Oct; 309(4):709-17. PubMed ID: 13679030
[TBL] [Abstract][Full Text] [Related]
14. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase.
Yee KW; O'Farrell AM; Smolich BD; Cherrington JM; McMahon G; Wait CL; McGreevey LS; Griffith DJ; Heinrich MC
Blood; 2002 Oct; 100(8):2941-9. PubMed ID: 12351406
[TBL] [Abstract][Full Text] [Related]
15. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
Abrams TJ; Lee LB; Murray LJ; Pryer NK; Cherrington JM
Mol Cancer Ther; 2003 May; 2(5):471-8. PubMed ID: 12748309
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.
Weisberg E; Boulton C; Kelly LM; Manley P; Fabbro D; Meyer T; Gilliland DG; Griffin JD
Cancer Cell; 2002 Jun; 1(5):433-43. PubMed ID: 12124173
[TBL] [Abstract][Full Text] [Related]
17. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.
Wisniewski D; Lambek CL; Liu C; Strife A; Veach DR; Nagar B; Young MA; Schindler T; Bornmann WG; Bertino JR; Kuriyan J; Clarkson B
Cancer Res; 2002 Aug; 62(15):4244-55. PubMed ID: 12154026
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.
Grundler R; Thiede C; Miething C; Steudel C; Peschel C; Duyster J
Blood; 2003 Jul; 102(2):646-51. PubMed ID: 12663439
[TBL] [Abstract][Full Text] [Related]
19. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).
Kelly LM; Yu JC; Boulton CL; Apatira M; Li J; Sullivan CM; Williams I; Amaral SM; Curley DP; Duclos N; Neuberg D; Scarborough RM; Pandey A; Hollenbach S; Abe K; Lokker NA; Gilliland DG; Giese NA
Cancer Cell; 2002 Jun; 1(5):421-32. PubMed ID: 12124172
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
